Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data [Yahoo! Finance]
Hoth Therapeutics, Inc. (HOTH)
Company Research
Source: Yahoo! Finance
pre-clinical research data demonstrating the potential of its investigational therapeutic candidate, HT-ALZ, to treat Alzheimer's disease (AD). Hoth Therapeutics' HT-ALZ uses a novel mechanism of action targeting the Substance P/Neurokinin 1 Receptor pathway to treat neuroinflammation and cognitive deficits associated with AD. In preclinical models, it was observed that HT-ALZ reduces soluble Aß levels (an important biomarker for the improvement of neurodegeneration in AD patients) in the brain's interstitial fluid. HT-ALZ significantly reduces anxiety-like behavior and enhances cognitive function. In the past year, shares of HOTH have plunged 37.8% compared with the industry's 9.4% decline. Image Source: Zacks Investment Research Pe the company, analysis of pre-clinical research data demonstrated HT-ALZ's massive potential to improve memory tasks, which could be a breakthrough in the treatment of AD patients. HOTH reported that the cognitive benefits provided by HT-ALZ th
Show less
Read more
Impact Snapshot
Event Time:
HOTH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HOTH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HOTH alerts
High impacting Hoth Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HOTH
News
- Hoth Therapeutics, Inc. (NASDAQ: HOTH) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $4.00 price target on the stock.MarketBeat
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross ProceedsPR Newswire
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment [Yahoo! Finance]Yahoo! Finance
- Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity TreatmentPR Newswire
HOTH
Sec Filings
- 4/22/24 - Form 424B3
- 4/22/24 - Form EFFECT
- 4/11/24 - Form S-1
- HOTH's page on the SEC website